Susan Galbraith (AstraZeneca)
June 28, 2021 09:43 AM EDT
People

As­traZeneca CEO Pas­cal So­ri­ot taps vet­er­an can­cer re­searcher Su­san Gal­braith for top on­col­o­gy post

John Carroll

Editor & Founder

When Su­san Gal­braith joined the can­cer R&D team at As­traZeneca in 2010, the phar­ma gi­ant was un­der­go­ing a bru­tal take­down at the hands of an­a­lysts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times